Growing Medical Portfolio Avicanna’s diversified product line spans medical cannabis formulations (RHO Phyto), dermatology and neurology drug candidates, and the MyMedi.ca care platform, highlighting multiple cross-sell opportunities to healthcare providers, clinics, and hospitals seeking cannabinoid-based therapies and patient support services.

Global Expansion Potential With a national Canadian footprint for RHO Phyto and ongoing registrations in South American markets for Trunerox, Avicanna presents sales channels in multiple regions; BD teams can prioritize partnerships, distributors, and reimbursement pathways in untapped international markets.

Integrated Healthcare MyMedi.ca offers pharmacist-led patient support and access programs, suggesting collaboration with payer networks, clinics, and government-funded healthcare programs to expand reimbursement, education, and patient adherence for cannabis-based therapies.

Financially Strategic Growth Recent revenue indicators and a growing pipeline alongside a formal CFO appointment signal organizational capacity to scale sales efforts, pursue larger pharmaceutical collaborations, and secure co-development or licensing deals for indication-specific candidates.

Tech Enabled Selling Existing tech stack (Salesforce, NetSuite, WooCommerce, and digital content tools) enables streamlined CRM, ERP, e-commerce, and digital education campaigns, allowing targeted outreach to medical professionals, clinics, and pharmacies with data-driven account plans.